The heart’s ability to adapt metabolically in response to physiological and pathological stimuli has long been a subject of intense scientific scrutiny. Heart cells are highly dependent on an intricate balance of energy production pathways to maintain proper function. Among these, glycolysis—the process by which glucose is broken down to produce energy—is crucial, especially under stress conditions. Disruptions in glycolytic flux are often associated with detrimental cardiac remodeling, such as hypertrophy, a condition characterized by enlarged cardiac muscle cells that can progress to heart failure.

At the core of this study lies Yin Yang 1 (YY1), a multifunctional transcription factor known to regulate a wide array of cellular processes, including proliferation, differentiation, and metabolism. YY1’s involvement in cardiac physiology, however, has remained poorly understood until now. The researchers elucidate how YY1 orchestrates an intricate signaling pathway involving Asprosin, a fasting-induced protein hormone, and phosphofructokinase platelet type (PFKP), a rate-limiting enzyme in glycolysis, to modulate energy metabolism in hypertrophic cardiomyocytes.

Asprosin, initially characterized as a glucogenic hormone secreted by white adipose tissue, has emerged as a critical metabolic regulator. This study reveals its novel paracrine role within cardiac tissue, mediating crosstalk between metabolic signaling and gene expression via YY1. By binding to YY1, Asprosin significantly influences the transcriptional activation of glycolytic genes, amplifying PFKP expression and accelerating glycolytic flux.

PFKP acts as a major control point within the glycolytic pathway, catalyzing the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate. Its activity effectively determines the pace of glycolysis, impacting ATP production and biosynthetic precursor availability. The overactivation of PFKP through the YY1/Asprosin signaling axis thus promotes heightened metabolic activity within cardiomyocytes, which becomes maladaptive during chronic stress, triggering pathological hypertrophy.

By employing a comprehensive suite of molecular techniques, including chromatin immunoprecipitation sequencing (ChIP-seq), metabolomic profiling, and advanced cardiac imaging, the research team meticulously mapped the regulatory network underpinning this axis. Their findings demonstrate that YY1 directly binds to the promoter region of the PFKP gene, facilitating transcriptional upregulation in response to Asprosin signaling. This transcriptional cascade intensifies glycolytic metabolism, causing an energetic imbalance that propels cardiomyocyte enlargement and maladaptive remodeling.

Intriguingly, mouse models genetically modified to overexpress Asprosin in cardiac tissue developed pronounced hypertrophic phenotypes characterized by increased heart size, fibrosis, and reduced cardiac output. Conversely, silencing either YY1 or PFKP in these models effectively mitigated hypertrophy, underscoring the therapeutic potential of targeting components within this axis.

The study also delves into the signaling intermediates modulated by YY1 and Asprosin, including AMP-activated protein kinase (AMPK) and hypoxia-inducible factor 1-alpha (HIF-1α). It appears that YY1 activation enhances glycolytic flux partly through cross-regulation of these metabolic sensors, establishing a feedback loop that exacerbates metabolic dysfunction during pathological stress.

This metabolic dysregulation correlates with an increase in reactive oxygen species (ROS) production and mitochondrial dysfunction, further compounding cellular stress and contributing to the progression of cardiac hypertrophy. Through sophisticated electron microscopy and mitochondrial respiration assays, the authors revealed that mitochondrial integrity is compromised when the YY1/Asprosin/PFKP axis is hyperactivated.

Beyond its implications for cardiac hypertrophy, this research expands the understanding of Asprosin’s systemic roles, implicating it as a key mediator in metabolic diseases linked to cardiovascular complications. Elevated circulating Asprosin levels have previously been reported in obesity and type 2 diabetes; thus, its involvement in heart disease may represent a unifying mechanism driven by metabolic derangements.

The translational significance of these findings is profound. By dissecting the molecular players involved in the YY1/Asprosin/PFKP axis, this work paves the way for innovative therapeutic strategies aimed at modulating glycolytic metabolism within the heart. Pharmacological inhibitors targeting PFKP or blocking Asprosin interactions could potentially arrest or reverse maladaptive cardiac hypertrophy, offering hope for millions affected by heart failure worldwide.

Furthermore, this study exemplifies the power of integrative multi-omics approaches coupled with precise in vivo modeling to unravel complex biological networks. The identification of YY1 as a master transcriptional regulator within the metabolic landscape of the heart underscores the intricate dependency of transcriptional control and cellular bioenergetics in disease pathology.

Future investigations will be needed to explore how this axis interacts with other metabolic regulators, such as fatty acid oxidation and mitochondrial biogenesis pathways. Understanding the broader metabolic rewiring associated with YY1/Asprosin/PFKP axis modulation could reveal additional therapeutic targets and biomarkers for early detection of pathological hypertrophic remodeling.

In conclusion, the discovery of the YY1/Asprosin/PFKP axis as a critical modulator of glycolytic metabolism that exacerbates pathological cardiac hypertrophy represents a paradigm shift in cardiovascular biology. This sophisticated regulatory circuit not only links metabolic signaling and gene expression but also provides a timely target for combating one of the leading causes of morbidity and mortality worldwide—the progression of cardiac hypertrophy to heart failure. The study charts a new course for metabolic therapeutics tailored to the complexities of cardiac disease, exemplifying the fusion of molecular discovery and clinical applicability.

Subject of Research: Cardiac metabolism and pathological hypertrophy mechanisms.

Article Title: YY1/Asprosin/PFKP axis regulates glycolytic metabolic and exacerbates pathological cardiac hypertrophy.

Article References:

Tong, M., Liu, X., Yu, Y. et al. YY1/Asprosin/PFKP axis regulates glycolytic metabolic and exacerbates pathological cardiac hypertrophy.
Nat Commun (2026). https://doi.org/10.1038/s41467-026-71197-2

Image Credits: AI Generated

The heart’s relentless demand for energy hinges on mitochondrial efficiency and metabolic homeostasis. Cardiomyocytes, the beating cells of the heart, rely heavily on their mitochondria to generate adenosine triphosphate (ATP), the cellular energy currency, through oxidative phosphorylation. However, the precise molecular regulators coordinating mitochondrial function in the heart remain only partially understood. LncRNAs, once dismissed as transcriptional noise, have emerged as potent regulators of gene expression and cellular metabolism. In this study, the researchers focused on Cpat, a cardiomyocyte-specific lncRNA, hypothesizing its involvement in mitochondrial dynamics.

Using a combination of transcriptomic analyses and functional assays, the team first characterized the expression pattern of Cpat in cardiac tissue. They observed that Cpat is not only abundantly expressed in healthy cardiomyocytes but its levels markedly decrease in models of cardiac stress and failure. This downregulation hinted at a potential protective role of Cpat in heart function. Intriguingly, loss-of-function experiments showed that silencing Cpat precipitated drastic impairments in mitochondrial morphology and reduced ATP production, emphasizing the lncRNA’s critical contribution to mitochondrial bioenergetics.

Delving deeper into the molecular mechanisms, the study unveiled that Cpat exerts its effects by modulating the post-translational acetylation of citrate synthase (CS), a pivotal enzyme in the tricarboxylic acid (TCA) cycle. Acetylation of CS is a reversible modification influencing its enzymatic activity, and aberrant acetylation can significantly disrupt cellular metabolism. Through RNA immunoprecipitation and acetylation assays, the authors demonstrated that Cpat physically associates with CS, effectively targeting it to regulate its acetylation status. This interaction preserved CS activity, ensuring optimal flux through the TCA cycle and sustained energy production.

The researchers employed sophisticated in vivo models, including genetically engineered mice deficient in Cpat specifically in cardiomyocytes. These animals exhibited profound cardiac dysfunction, characterized by diminished ejection fraction and overt signs of heart failure. Mitochondrial examination revealed fragmented and swollen organelles with impaired respiratory capacity. Notably, restoring Cpat levels in these models via gene therapy restored mitochondrial function and significantly improved cardiac performance, underscoring Cpat’s therapeutic potential.

One of the most striking aspects of this study is the elucidation of how lncRNAs can directly modulate the acetylation of metabolic enzymes. While protein acetylation is predominantly governed by the balance of acetyltransferases and deacetylases, the finding that a non-coding RNA can influence this modification challenges existing paradigms. Cpat appears to act as a molecular scaffold or guide, directing specific acetylation events on citrate synthase, which adds a new layer of regulatory complexity in cardiometabolic control and exemplifies the multifaceted roles of lncRNAs in cellular physiology.

The implications of this discovery extend beyond basic science; mitochondrial dysfunction is a hallmark of numerous cardiac pathologies, including ischemic heart disease, diabetic cardiomyopathy, and dilated cardiomyopathy. Therapeutic strategies aimed at stabilizing mitochondrial metabolism could therefore revolutionize treatment paradigms. The identification of Cpat as a key regulator offers a novel target for drug development, with the potential to fine-tune mitochondrial enzyme activity and improve cardiac resilience under stress.

Furthermore, the study highlights the importance of epigenetic and post-translational modifications in cardiac metabolism regulation, urging the scientific community to explore non-coding RNAs as critical modulators rather than passive genomic elements. Such insights could lead to a new class of RNA-based therapeutics designed to manipulate specific protein modifications and restore metabolic balance in diseased hearts, providing precision medicine approaches for cardiovascular disorders.

In addition to mitochondrial effects, Cpat was found to influence the broader cardiac transcriptome, potentially via interaction networks extending beyond citrate synthase. Transcriptomic profiling revealed alterations in genes involved in oxidative stress responses, calcium signaling, and mitochondrial biogenesis upon Cpat depletion. These findings suggest that Cpat may serve as a central hub integrating metabolic and signaling pathways crucial for cardiomyocyte adaptability and survival.

Importantly, the study utilized cutting-edge technologies, including CRISPR-based gene editing, advanced microscopy for mitochondrial imaging, and mass spectrometry to analyze protein acetylation patterns with unprecedented resolution. These technological innovations allowed the team to dissect the delicate interplay between RNA molecules and protein modifications within the dynamic intracellular environment, setting new standards for molecular cardiology research.

The identification of Cpat’s role also raises fascinating questions about the evolutionary conservation of lncRNA-mediated regulation of metabolism. Comparative analyses hinted that functional analogs of Cpat may exist across mammalian species, suggesting that lncRNA-dependent control of mitochondrial enzymes is an evolutionarily conserved mechanism ensuring cardiac energy homeostasis. Future research may focus on cross-species validation and exploring how such regulatory circuits evolved to meet the high-energy demands of the vertebrate heart.

Moreover, the translational potential of Cpat-focused therapy is bolstered by the demonstration that synthetic mimics or gene therapy vectors can restore mitochondrial function in preclinical models. This opens the possibility of developing clinicians’ tools to treat heart failure patients with impaired mitochondrial metabolism by harnessing the molecular machinery governed by lncRNAs, potentially improving survival and quality of life.

The work by Yu and colleagues also emphasizes the necessity of incorporating lncRNA research into the broader framework of cardiovascular medicine, an area traditionally dominated by protein-centric studies. As the heart is an organ exquisitely sensitive to metabolic perturbations, understanding how non-coding RNAs regulate key metabolic enzymes provides a fresh conceptual lens through which heart disease mechanisms can be examined and targeted.

While this study provides compelling evidence of Cpat’s critical function, questions remain about the exact structural basis of its interaction with citrate synthase and whether other mitochondrial enzymes are similarly regulated by lncRNAs. Detailed structural biology investigations and expanded proteomic screens are warranted to fully uncover the spectrum of lncRNA-protein interactions in cardiac mitochondria and their physiological relevance.

In conclusion, the discovery of cardiomyocyte lncRNA Cpat as a guardian of mitochondrial function via targeted modulation of citrate synthase acetylation represents a significant leap forward in cardiac molecular biology. It underscores the intricate and previously underappreciated roles of non-coding RNAs in maintaining the delicate balance of energy metabolism fundamental to heart health. This landmark study not only enriches our scientific understanding but also paves the way for innovative RNA-based therapies against debilitating cardiovascular diseases.

Subject of Research: Cardiomyocyte long non-coding RNA and mitochondrial regulation.

Article Title: Cardiomyocyte lncRNA Cpat maintains cardiac homeostasis and mitochondria function by targeting citrate synthase acetylation.

Article References:
Yu, F., Duan, J., Lou, Z. et al. Cardiomyocyte lncRNA Cpat maintains cardiac homeostasis and mitochondria function by targeting citrate synthase acetylation. Nat Commun 16, 9022 (2025). https://doi.org/10.1038/s41467-025-64072-z

Image Credits: AI Generated